Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00311376 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 416
- Enrollment target
NCT00311376 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 416 participants.
The verdict
NCT00311376, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 416 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients.
Interventions
- BIOLOGICAL botulinum toxin Type A (200U)
- BIOLOGICAL botulinum toxin Type A (300U)
- OTHER Normal Saline (Placebo); botulinum toxin Type A (200U)
- OTHER Normal Saline (Placebo); botulinum toxin Type A (300U)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 416 participants |
| Start Date | 2006-08 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00311376
The ClinicalTrials.gov registry entry for NCT00311376 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 416 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which botulinum toxin Type A (200U) is the first listed.
NCT00311376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00311376 about?
NCT00311376 is a clinical study titled "Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder". The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients.
What is the current status of trial NCT00311376?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 416 participants. The study started on 2006-08. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00311376?
The interventions under investigation include: botulinum toxin Type A (200U) (BIOLOGICAL), botulinum toxin Type A (300U) (BIOLOGICAL), Normal Saline (Placebo); botulinum toxin Type A (200U) (OTHER), Normal Saline (Placebo); botulinum toxin Type A (300U) (OTHER).
Who is sponsoring clinical trial NCT00311376?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.